Columbus Oncology and Hematology Associates Inc

Summary

Columbus Oncology and Hematology Associates Inc is a medical facility located in Columbus, Ohio. This center is recognized for care of Lung Cancer, Breast Cancer, Cancer, Ovarian Cancer, Breast cancer and other specialties. Columbus Oncology and Hematology Associates Inc is involved with conducting 221 clinical trials across 361 conditions. There are 8 research doctors associated with this hospital, such as Timothy D. Moore, Aine E. Clements, Anitha S. Nallari, and Chaoyang Li.

Top PIs

Clinical Trials running at Columbus Oncology and Hematology Associates Inc

Bladder Cancer

Ovarian Cancer

Lung Cancer

Breast Cancer

Cancer

Breast cancer

Melanoma

Bladder Carcinoma

Multiple Myeloma

Esophageal cancer

Blood Test and Immunotherapy

for Bladder Cancer

This phase II/III trial examines whether patients who have undergone surgical removal of bladder, kidney, ureter or urethra, but require an additional treatment called immunotherapy to help prevent their urinary tract (urothelial) cancer from coming back, can be identified by a blood test. Many types of tumors tend to lose cells or release different types of cellular products including their DNA which is referred to as circulating tumor DNA (ctDNA) into the bloodstream before changes can be seen on scans. Health care providers can measure the level of ctDNA in blood or other bodily fluids to determine which patients are at higher risk for disease progression or relapse. In this study, a blood test is used to measure ctDNA and see if there is still cancer somewhere in the body after surgery and if giving a treatment will help eliminate the cancer. Immunotherapy with monoclonal antibodies, such as nivolumab and relatlimab, can help the body's immune system to attack the cancer, and can interfere with the ability of tumor cells to grow and spread. This trial may help doctors determine if ctDNA measurement in blood can better identify patients that need additional treatment, if treatment with nivolumab prolongs patients' life and whether the additional immunotherapy treatment with relatlimab extends time without disease progression or prolongs life of urothelial cancer patients who have undergone surgical removal of their bladder, kidney, ureter or urethra.

Recruiting

1 award

Phase 2 & 3

10 criteria

Immunotherapy + Targeted Therapy

for Genitourinary Cancers

This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the body. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib, nivolumab, and ipilimumab may work better in treating patients with genitourinary tumors that have no treatment options compared to giving cabozantinib, nivolumab, or ipilimumab alone.

Recruiting

1 award

Phase 2

21 criteria

Blood Sample Collection

for Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in the laboratory may help researchers develop tests for the early detection of cancers.

Recruiting

1 award

N/A

9 criteria